Atara Biotherapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Atara Biotherapeutics, Inc.
After paying $45m upfront, the French firm has beaten off considerable competition to seal the European, Middle East and African rights to tabelecleucel which will be filed next month for Epstein-Barr virus-positive post-transplant lymphoproliferative disease.
The Pink Sheet's EU accelerated assessment tracker has been updated to include developments relating to experimental products from Atara, Calliditas, and Roche.
The outcomes of a handful of requests for accelerated assessment at the European Medicines Agency appear not yet to be in the public domain. In the meantime, there's been good for news for Atara's tab-cel and a switch to standard review for Nefecon from Calliditas.
Two companies are set to learn whether the European Medicines Agency will agree that their planned EU marketing applications merit an accelerated assessment.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Nina Biotherapeutics, Inc.
- Pinta Biotherapeutics, Inc.
- Santa Maria Biotherapeutics, Inc.